The PROPHETIC study is a prospective, multi-center, international clinical study aimed at
developing an algorithm to predict patient outcomes. The study involves analyzing the
proteomic profiles of patients undergoing therapy to assess the likelihood of clinical
benefit from their prescribed treatment. Blood samples are collected prior to and during
the treatment period and analyzed as part of the ongoing development of thealgorithm.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04056247.
The goal of this research study is to develop an algorithm that predicts the patient's
treatment outcome.This algorithm will serve as a tool for physicians when making
treatment decisions, specifically for stage IV NSCLC and malignant melanoma patients
receiving anti-cancer treatments. The investigators also aim to identify the metabolic
pathways that could lead to better therapeutic options. The patients will be given their
treatment according to the institute's standard of care. The patients will provide two
blood samples and clinical data will be collected from their medical records.
In the first part of the trial, the data obtained from the blood samples and the medical
records of the patients will be used to develop the prediction algorithm, and in the
second part of the trial, the algorithm will be validated by comparing the objective
response rate of the patients to the theoretical response prediction of the algorithm.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationOncoHost Ltd.
